OptiBiotix Health PLC License agreement for LPLDL® in Japan (2614E)
July 03 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 2614E
OptiBiotix Health PLC
03 July 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
License agreement for LP(LDL) (R) in Japan
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd. ("ProBiotix"), has signed a non-exclusive license
agreement with Tenshindo, Co. Ltd. ("Tenshindo") for the use of
Lactobacillus plantarum LP(LDL) (R) ("LP(LDL) (R)") in
cardiovascular food supplements in Japan.
Tenshindo is a manufacturer of functional food and cosmetics
products founded in Japan in 1986. LP(LDL) (R) will be the active
ingredient in a novel cardiovascular health product that Tenshindo
will add to its current portfolio of over 50 products. Tenshindo
and ProBiotix will work together to obtain an authorised
cardiovascular health claim for LP(LDL) (R) from the Japanese
authorities, based on the existing clinical and market evidence on
the strain.
This is the first end product application deal in Japan emerging
from ProBiotix's agreement with the local distributor EIWA Trading
Corporation in February 2019 (RNS: 11 February 2019) to distribute
LP(LDL) (R) in the country, and part of the Company's strategy to
include LP(LDL) (R) in a wide range of cardiovascular health
supplements, and in food, dairy, and beverage products across the
world. EIWA and ProBiotix are working together to replicate this
model with different partners and different applications in the
Japanese market.
Dr. Luis Gosalbez, Business Development Director of OptiBiotix,
commented: "We are pleased to announce this deal with Tenshindo,
which will mean our first LP(LDL) (R) finished product placement on
the Japanese market.
Obtaining an authorised cardiovascular health claim for LP(LDL)
(R) from Japanese authorities will not only be highly advantageous
from the commercial point of view, but also an important
endorsement for ProBiotix's science. Tenshindo, with over 30 years
of experience in this market, are an excellent commercial and
regulatory partner to make the most of this opportunity."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Tel: 0203 859 7725
goetzpartners securities Limited
Ulrich Kinzel
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRELLFBKDFXBBL
(END) Dow Jones Newswires
July 03, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024